Document is current
Any future updates will be listed below
-
Authors
Senna, Maryanne
Soung, Jennifer
Figueras, Ignasi
King, Brett
Kinoshita-Ise, Misaki
Hanna, Sameh
Wu, Wenyu
Wajsbrot, Dalia
Woodworth, Deborah
Wolk, Robert
Chaudhry, Alanna
Lejeune, Alexandre
Tran, Helen
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03732807 at ClinicalTrials.govnct04006457 at ClinicalTrials.govDocuments that mention this clinical trial
Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
https://doi.org/10.1007/s40257-026-01029-y
Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
https://doi.org/10.1007/s40257-024-00846-3
Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The ALLEGRO Phase 2b/3 Randomized Clinical Trial
https://doi.org/10.1007/s40257-024-00899-4
Impact of Previous Alopecia Areata Treatment on Efficacy Responses up to Week 48 Following Ritlecitinib Treatment: A Post Hoc Analysis
https://doi.org/10.1007/s13555-024-01260-7
Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development
https://doi.org/10.1007/s40262-023-01318-3
nct04517864 at ClinicalTrials.govDocuments that mention this clinical trial
Responses to Tetanus and Meningococcal Vaccines in Patients with Alopecia Areata Treated with Ritlecitinib
https://doi.org/10.1007/s13555-025-01648-z
Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
https://doi.org/10.1007/s40257-026-01029-y
Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
https://doi.org/10.1007/s40257-024-00846-3
nct02974868 at ClinicalTrials.govDocuments that mention this clinical trial
Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
https://doi.org/10.1007/s40257-026-01029-y
Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
https://doi.org/10.1007/s40257-024-00846-3
Documents that mention this clinical trial
Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
https://doi.org/10.1007/s40257-026-01029-y
Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
https://doi.org/10.1007/s40257-024-00846-3
Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development
https://doi.org/10.1007/s40262-023-01318-3
New drugs under investigation for the treatment of alopecias
https://doi.org/10.1080/13543784.2019.1568989
-
Funding
Funding for this research was provided by:
Pfizer
- License Information
-
More Information
Article History
Received: 20 February 2026
Accepted: 24 March 2026
First Online: 31 March 2026
Declarations
:
: Maryanne Senna has served on advisory boards and/or is a consultant and/or is a clinical trial investigator or a speaker for AbbVie, Arena Pharmaceuticals, Concert Pharmaceuticals Inc, Eli Lilly and Company, Inmagene, LEO Pharma, Merck, Pfizer Inc, Sun Pharmaceutical, and Kintor. She is a scientific advisor for BiologicsMD. Jennifer Soung is a speaker for Celgene, Regeneron/Sanofi, and Ortho Dermatologics; a speaker and investigator for Amgen, AbbVie, and Pfizer; a speaker, investigator, and advisor for Eli Lilly; an investigator and advisor for LEO Pharma; an investigator, speaker, and consultant for Novartis; an investigator for UCB, Janssen, Kyowa Kirin, KoBioLabs, and Castle Biosciences; an investigator and consultant for Dermavant; a speaker and consultant for Bristol Myers Squibb; and a speaker, investigator, and a consultant for Arcutis. Ignasi Figueras has served as an advisory board member, consultant, and/or investigator for AbbVie, Eli Lilly and Company, LEO Pharma, L’Oréal, Pfizer, Novartis, Sanofi, Celgene, Amgen, Galderma, and Gebro Pharma, and speaker for AbbVie, Eli Lilly and Company, LEO Pharma, Pfizer, Sanofi, Novartis, Sobi, Pierre Fabre, La Roche-Posay, Galderma, and Gebro Pharma. Brett King has served on advisory boards, is a consultant, is a clinical trial investigator, and/or is on a data monitoring committee for AbbVie, AltruBio, Inc, Almirall, AnaptysBio, Arena Pharmaceuticals, Aslan Pharmaceuticals, Bioniz Therapeutics, Bristol Myers Squibb, Concert Pharmaceuticals, Inc, Equillium, Horizon Therapeutics, Eli Lilly and Company, Incyte Corp, Janssen Pharmaceuticals, LEO Pharma, Merck, Otsuka/Visterra, Inc, Pfizer Inc, Q32 Bio, Inc, Regeneron, Sanofi Genzyme, Sun Pharmaceutical, TWi Biotechnology, Inc, Viela Bio, and Ventyx Biosciences, Inc; and has served on speakers bureaus for AbbVie, Incyte, Eli Lilly, Pfizer, Regeneron, and Sanofi Genzyme. Misaki Kinoshita-Ise is a clinical trial investigator for AbbVie, Eli Lilly Japan, Pfizer, and Bristol Myers Squibb, and a speaker for Eli Lilly Japan and Pfizer. Sameh Hanna is a clinical trialist with AbbVie, Lilly, Lumenis, and Pfizer, and has received honoraria for speaking/consulting from AbbVie, Lilly, and Pfizer. Wenyu Wu is a clinical trial investigator and a speaker for AbbVie, Eli Lilly, and Pfizer. Dalia Wajsbrot, Deborah Woodworth, Robert Wolk, Alanna Chaudhry, Alexandre Lejeune, and Helen Tran are employees of, and may hold stock or stock options in, Pfizer Inc.
: Ethics approval was obtained for the individual studies included in the analysis. The study was performed in accordance with the ethical standards as provided in the Declaration of Helsinki.
: Informed consent was obtained from all participants of the individual studies included in this analysis.
: Patients signed informed consent regarding publishing their data.
: Upon request, and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions, and exceptions, Pfizer may also provide access to the related individual deidentified participant data. See for more information.
: The code used for model development is not publicly available. Additional details regarding the model may be provided by the authors upon reasonable request.
: All authors contributed to the concept and design of the study, to data analysis and interpretation, and to critical revision of the publication, and all authors read and approved the final manuscript.
